Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ).
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced that it will convene an extraordinary general meeting (EGM) on 12 February 2026 at 2:00 p.m., to be held in a hybrid format combining a physical meeting in Beijing and an online virtual meeting. To determine eligibility to attend and vote at the EGM, the company will close its register of H-shareholders from 9 to 12 February 2026, during which no transfers of H shares will be processed; only shareholders whose names appear on the H-share register on 12 February 2026, and who complete any necessary share transfers by 6 February 2026, will be entitled to participate and vote, clarifying procedural requirements for investors ahead of the meeting.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China with limited liability and listed in Hong Kong under stock code 2315. The company operates in the biopharmaceutical sector, with a focus on drug discovery and development, and is governed by a board comprising executive, non-executive, independent non-executive and employee directors.
Average Trading Volume: 1,445,352
Technical Sentiment Signal: Hold
Current Market Cap: HK$17.46B
See more insights into 2315 stock on TipRanks’ Stock Analysis page.